ClinicalTrials.Veeva

Menu

Ozonized Oil as Dietary Supplement in Macular Degeneration

A

Alba Di Pardo

Status

Active, not recruiting

Conditions

Maculopathy

Treatments

Dietary Supplement: High ozonide (HOO) ozonated oil

Study type

Observational

Funder types

Other

Identifiers

NCT06351033
ADP_012023

Details and patient eligibility

About

Macular degeneration, also called age-related macular degeneration (AMD), is a leading cause of visual impairment and severe vision loss.

AMD is a disease with a multifactorial etiology. The main factors which, associated with the genetic ones, increase the risk of WMD onset are represented by smoking, obesity, hypertension, cardio-vascular diseases, a diet rich in dietary fat and alcohol intake. From an organic point of view, AMD is a disease that affects the macular region of the retina, causing progressive loss of central vision.

Retinal cells are characterized by high oxygen consumption. Reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide and hydroxyl radical are the standard product of cellular metabolism within the mitochondria. Under physiological conditions, ROS are neutralized by a system of antioxidants. In case of cellular metabolism disturbances or insufficiency of the antioxidant system, an excess of ROS can be produced which contributes to oxidative stress, widely described as exerting deleterious effects on cells. The high oxygen requirement and low levels of antioxidant enzymes make the retina extremely sensitive to oxidative stress and more susceptible to cell death. Prevention of neuronal death in the retina becomes a crucial aspect for the management of WMD.

The treatment of choice for AMD today is the use of anti-VEGF (Vascular Endothelial Growth Factor) drugs, they are effective for neo-vascular AMD, acting on the inhibition of the angiogenic protein VEGF, which is produced in the retina and induced by hypoxia and other conditions. It is practice, however, to support the integration of nutritional supplements such as zinc, resveratrol, carotenoids such as lutein and zeaxanthin, vitamin E and Omega-3 fatty acids.

The aim of this study is to evaluate the efficacy of ozonated oil with high ozonides (HOO) administered orally as gastro-resistant capsules (O3Zone, GS Pharma, Malta), as an integrative and complementary treatment in patients affected by macular degeneration in the possible slowing of disease progression.

Full description

The aim of the study is to evaluate the efficacy of ozonated oil with high ozonides (HOO) administered orally as gastro-resistant capsules (O3Zone, GS Pharma, Malta), as an integrative and complementary treatment in patients affected by macular degeneration.

Field of view will be monitored to reveal the possible slowing of disease progression.

Enrollment

60 estimated patients

Sex

All

Ages

50 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Definite AMD diagnosis with documented disease progression within the past 6 months

  • Age: 50-85 years old
  • Ascertained differential diagnosis with the aid of diagnostic tools: fundus examination eye; analysis of the macular region using optical computed tomography (OCT)

Exclusion Criteria:

  • Psychiatric diseases
  • Type I and II diabetes
  • Patients with high refractive defects: myopia > 6 d; hyperopia > 4 d; astigmatism > 4 d
  • Corneal pathologies
  • Hereditary retinal diseases
  • Autoimmune diseases (uveitis)
  • Glaucoma
  • Oncological diseases
  • Liver and kidney disease
  • Inclusion in other clinical trials
  • Inability to understand informed consent and the purpose of the study
  • Women who are pregnant or who may become pregnant during treatment

Trial design

60 participants in 2 patient groups

Placebo
Description:
Placebo: control group made up of subjects affected by maculopathy - eligible according to the study protocol - subjected to traditional elective treatments only (including intravitreal Anti-VEGF injections).
Ozonized Oil
Description:
Ozonized Oil: intervention group made up of subjects affected by maculopathy - eligible according to the study protocol - subjected to the traditional treatments of choice (including anti-VEGF intravitreal injections) who receive supplementary treatment with the intake of HOO gastro-resistant capsules.
Treatment:
Dietary Supplement: High ozonide (HOO) ozonated oil

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems